Organic electroluminescent compound and organic electroluminescent device comprising the same
US-2024067618-A1 · Feb 29, 2024 · US
Substituted 1,3-benzothiazol-2(3H)-ones and [1,3]thiazolo[5,4-B]pyridin-2(1H)-ones as positive allosteric modulators of mGluR2
US8952005B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8952005-B2 |
| Application number | US-201314048608-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 8, 2013 |
| Priority date | Apr 29, 2010 |
| Publication date | Feb 10, 2015 |
| Grant date | Feb 10, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound according to Formula I wherein: R 1 is selected from the group consisting of —(CH 2 ) p cyclopropyl, —(CH 2 ) p cyclopentyl, —(CH 2 ) p cyclohexyl, —(CH 2 ) p piperidinyl, (CH 2 ) p phenyl, and C 1-6 alkyl, wherein each said cyclopropyl, cyclopentyl, cyclohexyl and alkyl is optionally substituted with 1-3 halo, C 1-6 alkyl, CF 3 , —C(…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8952005B2 cover?
- The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invent…
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification C07D417/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).